Enterprise Value

26.84M

Cash

9.485M

Avg Qtr Burn

-6.636M

Short % of Float

3.48%

Insider Ownership

3.38%

Institutional Own.

10.69%

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Vyleesi® (bremelanotide) MC4r Agonist Details
Sexual dysfunction, Sexual desire disorder, Influenza

Approved

Quarterly sales

PL9643 Details
Dry eye syndrome, Eye disease

Phase 3

Update

Bremelanotide + PDE5i Details
Erectile dysfunction

Phase 2

Data readout

PL8177 Details
Bowel disorder, Inflammatory disease, Chronic inflammatory disorder, Ulcerative colitis

Phase 2

Data readout

Bremelanotide + GLP-1 Details
Obesity, Metabolic disorder

Phase 2

Data readout

Bremelanotide Details
Diabetic Kidney Disease

Phase 2

Data readout

PL8177 Details
Eye disease , Inflammatory disease

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued